The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Kostyleva O.I.

N.N. Blokhin Russian Cancer Research Center, Moscow, Russia

Mushtenko V.V.

Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, Moscow, Russia

Kolpakov A.V.

Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, Moscow, Russia

Timofeev Y.S.

N.N. Blokhin Russian Cancer Research Center, Moscow, Russia

Kushlinskiĭ N.E.

Rossiĭskiĭ onkologicheskiĭ nauchnyĭ tsentr im. N.N. Blokhina RAMN, Moskva

Features of expression matrix metalloproteinases, their tissue inhibitors and renal cancer

Authors:

Kostyleva O.I., Mushtenko V.V., Kolpakov A.V., Timofeev Y.S., Kushlinskiĭ N.E.

More about the authors

Journal: Laboratory Service. 2017;6(1): 6‑13

DOI: 10.17116/labs2017616-13

Read: 2631 times

Download PDF (RU)
Contact the author
Table of contents

FEATURES OF EXPRESSION MATRIX METALLOPROTEINASES, THEIR TISSUE INHIBITORS AND RENAL CANCER
FEATURES OF EXPRESSION MATRIX METALLOPROTEINASES, THEIR TISSUE INHIBITORS AND RENAL CANCER

To cite this article:

Kostyleva OI, Mushtenko VV, Kolpakov AV, Timofeev YS, Kushlinskiĭ NE. Features of expression matrix metalloproteinases, their tissue inhibitors and renal cancer. Laboratory Service. 2017;6(1):6‑13. (In Russ.)
https://doi.org/10.17116/labs2017616-13

 
Подписка 2025 Лабораторная служба (Laboratory Service)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Features of differential diagnosis of onco­logical pathology at the outpatient stage. Russian Journal of Preventive Medi­cine. 2025;(2):93-95
Surgical mana­gement of patients with local recu­rrence of renal cancer. Prognostic factors of survival. P.A. Herzen Journal of Onco­logy. 2025;(3):20-24
The place of stereotactic radiotherapy in the treatment of renal cancer. P.A. Herzen Journal of Onco­logy. 2025;(4):86-90
Abstract:

A review of the literature is devoted to the role of the system of matrix metalloproteinases and their tissue inhibitors in renal carcinoma. Due to the absence of screening, diagnostic models for early diagnosis, as well as specific monitoring of relapse for renal tumors, the urgent task is the identification of new biomarkers of renal tumor. Recent studies demonstrate the prospects of using the system MMP/TIMP not only as a diagnostic but also a prognostic marker in some renal tumors, as well as to assess the effectiveness of targeting anticancer therapy.

Keywords:

MMP
TIMP
prognostic markers
renal carcinoma

Authors:

Kostyleva O.I.

N.N. Blokhin Russian Cancer Research Center, Moscow, Russia

Mushtenko V.V.

Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, Moscow, Russia

Kolpakov A.V.

Moscow State University of Medicine and Dentistry named after A.I. Evdokimov, Moscow, Russia

Timofeev Y.S.

N.N. Blokhin Russian Cancer Research Center, Moscow, Russia

Kushlinskiĭ N.E.

Rossiĭskiĭ onkologicheskiĭ nauchnyĭ tsentr im. N.N. Blokhina RAMN, Moskva

Close metadata

References:

  1. Gershtein ES. Clinical perspectives of tumor-associated proteases analysis in cancer patients. Spravochnik zaveduyushchego KDL. 2013;(11):17-24. (In Russ.)
  2. Baker AH, Ahonen M, Kahari VM. Potential applications of tissue inhibitor of metalloproteinase (TIMP) overexpression for cancer gene therapy. Adv Exp Med Biol. 2000;465:469-483. doi:10.1007/0-306-46817-4_41
  3. Basile DP, Donohoe D, Roethe K, Osborn JL. Renal ischemic injury results in permanent damage to peritubular capillaries and influences long-term function. Am J Physiol Renal Physiol. 2001;281(5):887-899. doi:10.1152/ajprenal.0050.2001
  4. Basile DP, Fredrich K, Weihrauch D, Hattan N, Chilian WM. Angiostatin and matrix metalloprotease expression following ischemic acute renal failure. Am J Physiol Renal Physiol. 2004;286(5):893-902. doi:10.1152/ajprenal.00328.2003
  5. Bengatta S, Arnould C, Letavernier E, Monge M, de Préneuf HM, Werb Z, Ronco P, Lelongt B. MMP9 and SCF protect from apoptosis in acute kidney injury. J Am Soc Nephrol. 2009;20(4):787-797. doi:10.1681/ASN.2008050515
  6. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000;2(10):737-744. doi:10.1038/35036374
  7. Bhuvarahamurthy V, Kristiansen GO, Johannsen M, Loening SA, Schnorr D, Jung K, Staack A. In situ gene expression and localization of metalloproteinases MMP1, MMP2, MMP3, MMP9, and their inhibitors TIMP1 and TIMP2 in human renal cell carcinoma. Oncol Rep. 2006;15(5):1379-1384. doi:10.3892/or.15.5.1379
  8. Chen F, Deng J, Liu X, Li W, Zheng J. Corrigendum: HCRP-1 regulates cell migration and invasion via EGFR-ERK mediated up-regulation of MMP-2 with prognostic significance in human renal cell carcinoma. Sci Rep. 2016;6:19412. doi:10.1038/srep19412
  9. Cheng HP, Duan YR, Li Y, Li XD, Zhu CY, Chen BP. Clinicopathological Significance of Matrix Metalloproteinase-2 Protein Expression in Renal Cell Carcinoma Patients. Anal Quant Cytopathol Histpathol. 2015;37(6):353-363. doi:10.3233/CBM-150566
  10. Cox JH, Starr AE, Kappelhoff R, Yan R, Roberts CR, Overall CM. Matrix metalloproteinase 8 deficiency in mice exacerbates inflammatory arthritis through delayed neutrophil apoptosis and reduced caspase 11 expression. Arthritis Rheum. 2010;62(12):3645-3655. doi:10.1002/art.27757
  11. Daniel C, Duffield J, Brunner T, Steinmann-Niggli K, Lods N, Marti HP. Matrix metalloproteinase inhibitors cause cell cycle arrest and apoptosis in glomerular mesangial cells. J Pharmacol Exp Ther. 2001;297(1):57-68.
  12. Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006;25(1):9-34. doi:10.1007/s10555-006-7886-9
  13. Deryugina EI, Quigley JP. Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions. Biochim Biophys Acta. 2010;1803(1):103-120. doi:10.1016/j.bbamcr.2009.09.017
  14. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N; AVOREN Trial investigators Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370(9605): 2103-2111. doi:10.1016/S0140-6736(07)61904-7
  15. Fanjul-Fernandez M, Folgueras AR, Cabrera S, Lopez-Otin C. Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochim Biophys Acta. 2009;1803(1):3-19. doi:10.1016/j.bbamcr.2009.07.004
  16. Gagliano N, Arosio B, Santambrogio D, Balestrieri MR, Padoani G, Tagliabue J, Masson S, Vergani C, Annoni G. Age-dependent expression of fibrosis-related genes and collagen deposition in rat kidney cortex. J Gerontol A Biol Sci Med Sci. 2000;55(8):365-372. doi:10.1093/gerona/55.8.B365
  17. Gawden-Bone C, Zhou Z, King E, Prescott A, Watts C, Lucocq J. Dendritic cell podosomes are protrusive and invade the extracellular matrix using metalloproteinase MMP-14. J Cell Sci. 2010;123(Pt 9):1427-1437. doi:10.1242/jcs.056515
  18. Gershtein ES, Kushlinskii NE. Clinical prospects of tumor-associated proteases and their tissue inhibitors investigation in oncologic patients. Annals of the Russian academy of medical sciences. 2013;68(5):16-27. doi:10.15690/vramn.v68i5.659
  19. Guan BZ, Yan RL, Huang JW, Li FL, Zhong YX, Chen Y, Liu FN, Hu B, Huang SB, Yin LH. Activation of G Protein Coupled Estrogen Receptor (GPER) Promotes the Migration of Renal Cell Carcinoma via the PI3K/AKT/MMP-9 Signals. Cell Adh Migr. 2015;Jan 14:0. doi:10.4161/19336918.2014.990781
  20. Haro H, Crawford HC, Fingleton B, Shinomiya K, Spengler DM, Matrisian LM. Matrix metalloproteinase-7-dependent release of tumor necrosis factor-alpha in a model of herniated disc resorption. J Clin Invest. 2000;105(2):143-150. doi:10.1172/jci7091
  21. He W, Tan RJ, Li Y, Wang D, Nie J, Hou FF, Liu Y. Matrix metalloproteinase-7 as a surrogate marker predicts renal Wnt/beta-catenin activity in CKD. J Am Soc Nephrol. 2012;23(2):294-304. doi:10.1681/asn.2011050490
  22. Hu K, Yang J, Tanaka S, Gonias SL, Mars WM, Liu Y. Tissue-type plasminogen activator acts as a cytokine that triggers intracellular signal transduction and induces matrix metalloproteinase-9 gene expression. J Biol Chem. 2006;281(4):2120-2127. doi:10.1074/jbc.m504988200
  23. Huang QB, Ma X, Li HZ, Ai Q, Liu SW, Zhang Y, Gao Y, Fan Y, Ni D, Wang BJ, Zhang X. Endothelial Delta-like 4 (DLL4) promotes renal cell carcinoma hematogenous metastasis. Oncotarget. 2014;5(10):3066-3075. doi:10.18632/oncotarget.1827
  24. Huang S, Van Arsdall M, Tedjarati S, McCarty M, Wu W, Langley R, Fidler IJ. Contributions of stromal metalloproteinase-9 to angiogenesis and growth of human ovarian carcinoma in mice. J Natl Cancer Inst. 2002;94(15):1134-1142. doi:10.1093/jnci/94.15.1134
  25. Kassiri Z, Oudit GY, Kandalam V, Awad A, Wang X, Ziou X, Maeda N, Herzenberg AM, Scholey JW. Loss of TIMP3 enhances interstitial nephritis and fibrosis. J Am Soc Nephrol. 2009;20(6):1223-1235. doi:10.1681/asn.2008050492
  26. Kawata N, Nagane Y, Igarashi T, Hirakata H, Ichinose T, Hachiya T, Takimoto Y, Takahashi S. Strong significant correlation between MMP-9 and systemic symptoms in patients with localized renal cell carcinoma. Urology. 2006;68(3):523-527. doi:10.1016/j.urology.2006.03.063
  27. Kim YH, Jung JC. Suppression of tunicamycin-induced CD44v6 ectodomain shedding and apoptosis is correlated with temporal expression patterns of active ADAM10, MMP-9 and MMP-13 proteins in Caki-2 renal carcinoma cells. Oncol Rep. 2012;28(5):1869-1874. doi:10.3892/or.2012.1986
  28. Kominsky SL, Doucet M, Thorpe M, Weber KL. MMP-13 is over-expressed in renal cell carcinoma bone metastasis and is induced by TGF-beta1. Clin Exp Metastasis. 2008;25(8):865-870. doi:10.1007/s10585-008-9202-2
  29. Li HL, Han L, Chen HR, Meng F, Liu QH, Pan ZQ, Bai J, Zheng JN. PinX1 serves as a potential prognostic indicator for clear cell renal cell carcinoma and inhibits its invasion and metastasis by suppressing MMP-2 via NF-kappaB-dependent transcription. Oncotarget. 2015;6(25):21406-21420. doi:10.18632/oncotarget.4011
  30. Liang L, Li L, Zeng J, Gao Y, Chen YL, Wang ZQ, Wang XY, Chang LS, He D. Inhibitory effect of silibinin on EGFR signal-induced renal cell carcinoma progression via suppression of the EGFR/MMP-9 signaling pathway. Oncol Rep. 2012;28(3):999-1005. doi:10.3892/or.2012.1874
  31. Limb GA, Matter K, Murphy G, Cambrey AD, Bishop PN, Morris GE, Khaw PT. Matrix metalloproteinase-1 associates with intracellular organelles and confers resistance to lamin A/C degradation during apoptosis. Am J Pathol. 2005;166(5):1555-1563. doi:10.1016/s0002-9440(10)62371-1
  32. Lin YW, Lee LM, Lee WJ, Chu CY, Tan P, Yang YC, Chen WY, Yang SF, Hsiao M, Chien MH. Melatonin inhibits MMP-9 transactivation and renal cell carcinoma metastasis by suppressing Akt-MAPKs pathway and NF-kappaB DNA-binding activity. J Pineal Res. 2016;60(3):277-290. doi:10.1111/jpi.12308
  33. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature. 1980;284(5751):67-68. doi:10.1038/284067a0
  34. Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol. 2011;7(12):684-696. doi:10.1038/nrneph.2011.149
  35. Lu Y, Liu S, Zhang S, Cai G, Jiang H, Su H, Li X, Hong Q, Zhang X, Chen X. Tissue inhibitor of metalloproteinase-1 promotes NIH3T3 fibroblast proliferation by activating p-Akt and cell cycle progression. Mol Cells. 2011;31(3):225-230. doi:10.1007/s10059-011-0023-9
  36. Ma JJ, Kong LM, Liao CG, Jiang X, Wang Y, Bao TY. Suppression of MMP-9 activity by NDRG2 expression inhibits clear cell renal cell carcinoma invasion. Med Oncol. 2012;29(5):3306-3313. doi:10.1007/s12032-012-0265-1
  37. Manicone AM, Huizar I, McGuire GK. Matrilysin (Matrix Metalloproteinase-7) regulates anti-inflammatory and antifibrotic pulmonary dendritic cells that express CD103 (alpha(E)beta(7)-integrin). Am J Pathol. 2009;175(6):2319-2331. doi:10.2353/ajpath.2009.090101
  38. Miyake H, Nishikawa M, Tei H, Furukawa J, Harada K, Fujisawa M. Significance of circulating matrix metalloproteinase-9 to tissue inhibitor of metalloproteinases-2 ratio as a predictor of disease progression in patients with metastatic renal cell carcinoma receiving sunitinib. Urol Oncol. 2014;32(5):584-588. doi:10.1016/j.urolonc.2014.01.016
  39. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A; RECORD-1 Study Group Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet. 2008;372(9637):449-456. doi:10.1016/s0140-6736(08)61039-9
  40. Motzer RJ, Hutson TE, Hudes GR, Figlin RA, Martini JF, English PA, Huang X, Valota O, Williams JA. Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma. Cancer Chemother Pharmacol. 2014;74(4):739-750. doi:10.1007/s00280-014-2539-0
  41. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356(2):115-124. doi:10.1056/nejmoa065044
  42. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69(3):562-573. doi:10.1016/j.cardiores.2005.12.002
  43. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem. 1999;274(31):21491-21494. doi:10.1074/jbc.274.31.21491
  44. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM. Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol. 2000;18(5):1135-1149.
  45. Patraki E, Cardillo MR. Quantitative immunohistochemical analysis of matrilysin 1 (MMP-7) in various renal cell carcinoma subtypes. Int J Immunopathol Pharmacol. 2007;20(4):697-705.
  46. Perez-Gracia JL, Prior C, Guillén-Grima F, Segura V, Gonzalez A, Panizo A, Melero I, Grande-Pulido E, Gurpide A, Gil-Bazo I, Calvo A. Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array. Br J Cancer. 2009;101(11):1876-1883. doi:10.1038/sj.bjc.6605409
  47. Perng DW, Chang KT, Su KC, Wu YC, Chen CS, Hsu WH, Tsai CM, Lee YC. Matrix metalloprotease-9 induces transforming growth factor-beta(1) production in airway epithelium via activation of epidermal growth factor receptors. Life Sci. 2011;89(5-6):204-212. doi:10.1016/j.lfs.2011.06.008
  48. Powell WC, Fingleton B, Wilson CL, Boothby M, Matrisian LM. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr Biol. 1999;9(24):1441-1447. doi:10.1016/s0960-9822(00)80113-x
  49. Ramankulov A, Lein M, Johannsen M, Schrader M, Miller K, Jung K. Plasma matrix metalloproteinase-7 as a metastatic marker and survival predictor in patients with renal cell carcinomas. Cancer Sci. 2008;99(6):1188-1194. doi:10.1111/j.1349-7006.2008.00802.x
  50. Ramnath N, Creaven PJ. Matrix metalloproteinase inhibitors. Curr Oncol Rep. 2004;6(2):96-102. doi:10.1007/s11912-004-0020-7
  51. Ramos-DeSimone N, Hahn-Dantona E, Sipley J, Nagase H, French DL, Quigley JP. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem. 1999;274(19):13066-13076. doi:10.1074/jbc.274.19.13066
  52. Sarkissian G, Fergelot P, Lamy PJ, Patard JJ, Culine S, Jouin P, Rioux-Leclercq N, Darbouret B. Identification of pro-MMP-7 as a serum marker for renal cell carcinoma by use of proteomic analysis. Clin Chem. 2008;54(3):574-581. doi:10.1373/clinchem.2007.090837
  53. Sato A, Nagase H, Obinata D, Fujiwara K, Fukuda N, Soma M, Yamaguchi K, Kawata N, Takahashi S. Inhibition of MMP-9 using a pyrrole-imidazole polyamide reduces cell invasion in renal cell carcinoma. Int J Oncol. 2013;43(5):1441-1446. doi:10.3892/ijo.2013.2073
  54. Shariat SF, Karam JA, Karakiewicz PI Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356(22):2271-2281. doi:10.1056/nejmoa066838
  55. Sherief MH, Low SH, Miura M, Kudo N, Novick AC, Weimbs T. Matrix metalloproteinase activity in urine of patients with renal cell carcinoma leads to degradation of extracellular matrix proteins: possible use as a screening assay. J Urol. 2003;169(4):1530-1534. doi:10.1097/01.ju.0000049201.91150.9d
  56. Si-Tayeb K, Monvoisin A, Mazzocco C, Lepreux S, Decossas M, Cubel G, Taras D, Blanc JF, Robinson DR, Rosenbaum J. Matrix metalloproteinase 3 is present in the cell nucleus and is involved in apoptosis. Am J Pathol. 2006;169(4):1390-1401. doi:10.2353/ajpath.2006.060005
  57. Stetler-Stevenson WG. Tissue inhibitors of metalloproteinases in cell signaling: metalloproteinase-independent biological activities. Sci Signal. 2008;1(27):re6. doi:10.1126/scisignal.127re6
  58. Sun GG, Wei CD, Jing SW, Hu WN. Interactions between filamin A and MMP-9 regulate proliferation and invasion in renal cell carcinoma. Asian Pac J Cancer Prev. 2014;15(8):3789-3795. doi:10.7314/apjcp.2014.15.8.3789
  59. Swee M, Wilson CL, Wang Y, McGuire JK, Parks WC. Matrix metalloproteinase-7 (matrilysin) controls neutrophil egress by generating chemokine gradients. J Leukoc Biol. 2008;83(6):1404-1412. doi:10.1189/jlb.0108016
  60. Tan RJ, Zhou D, Zhou L, Liu Y. Wnt/beta-catenin signaling and kidney fibrosis. Kidney Int Suppl. (2011). 2014;4(1):84-90. doi:10.1038/kisup.2014.16
  61. Tan RJ, Liu Y. Matrix metalloproteinases in kidney homeostasis and diseases. Am J Physiol Renal Physiol. 2012;302(11):1351-1361. doi:10.1152/ajprenal.00037.2012
  62. Tarín C, Gomez M, Calvo E, López JA, Zaragoza C. Endothelial nitric oxide deficiency reduces MMP-13-mediated cleavage of ICAM-1 in vascular endothelium: a role in atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29(1):27-32. doi:10.1161/atvbaha.108.169623
  63. Wang X, Zhou Y, Tan R, Xiong M, He W, Fang L, Wen P, Jiang L, Yang J. Mice lacking the matrix metalloproteinase-9 gene reduce renal interstitial fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol. 2010;299(5):973-982. doi:10.1152/ajprenal.00216.2010
  64. Wickstrom SA, Alitalo K, Keski-Oja J. Endostatin signaling and regulation of endothelial cell-matrix interactions. Adv Cancer Res. 2005;94:197-229. doi:10.1016/s0065-230x(05)94005-0
  65. Xu X, Jackson PL, Tanner S, Hardison MT, Abdul Roda M, Blalock JE, Gaggar A. A self-propagating matrix metalloprotease-9 (MMP-9) dependent cycle of chronic neutrophilic inflammation. PLoS One. 2011;6(1):e15781. doi:10.1371/journal.pone.0015781
  66. Yen JH, Khayrullina T, Ganea D. PGE2-induced metalloproteinase-9 is essential for dendritic cell migration. Blood. 2008;111(1):260-270. doi:10.1182/blood-2007-05-090613
  67. Zhang Y, Wu XH, Cao GH, Li S. Relationship between expression of matrix metalloproteinase-9 (MMP-9) and angiogenesis in renal cell carcinoma. Ai Zheng. 2004;23(3):326-329.
  68. Zhou D, Tan RJ, Zhou L, Li Y, Liu Y. Kidney tubular beta-catenin signaling controls interstitial fibroblast fate via epithelial-mesenchymal communication. Sci Rep. 2013;3:1878. doi:10.1038/srep01878.
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.